Hidden potential: How Existing Drugs Could Transform MS Treatment

Join us for a dynamic panel discussion exploring innovative approaches to treating progressive MS through three research projects being funded by the International Progressive MS Alliance. This webcast brings together leading researchers who are investigating how existing medications might unlock new therapeutic possibilities for MS. Ellen Mowry will share insights into her research on targeting agonists of the glucagon-like peptide-1 (GLP-1) receptor, a promising avenue for modulating immune responses and neuroprotection in MS. Wee Yong will discuss his development project testing salbutamol, a common asthma medication, both alone and in combination with ibudilast, for their potential to slow progression in MS. Laura Airas will describe her clinical trial examining hydroxychloroquine and its ability to reduce glial activation, a key contributor to neurodegeneration in progressive MS. This conversation will highlight the potential of repurposed drugs to accelerate treatment options, reduce development timelines, and offer new hope to those living with progressive MS. The International Progressive MS Alliance Webcasts are sponsored by Sanofi and Genentech. MSIF’s work to promote the activities of the International Progressive MS Alliance is made possible by grants from Merck, Novartis, Roche and Sanofi.